K. Ishida

发表

Supplemented Chondroitin Sulfate and Hyaluronic Acid Suppress Mineralization of the Chondrogenic Cell Line, ATDC5, via Direct Inhibition of Alkaline Phosphatase.

Toshiya Kudo, S. Nakatani, M. Kakizaki, 2017, Biological & pharmaceutical bulletin.

Exploitation of heparanase inhibitors from microbial metabolites using an efficient visual screening system.

K. Ishida, H. Osada, S. Simizu, 2004, The Journal of antibiotics.

Structure-based design of a selective heparanase inhibitor as an antimetastatic agent.

M. Sodeoka, K. Ishida, H. Osada, 2004, Molecular cancer therapeutics.

Self-association and unique DNA binding properties of the anti-cancer agent TAS-103, a dual inhibitor of topoisomerases I and II.

K. Ishida, T. Asao, 2002, Biochimica et biophysica acta.

Novel heparan sulfate mimetic compounds as antitumor agents.

K. Ishida, H. Osada, S. Simizu, 2004, Chemistry & biology.

Expression of heparanase in human tumor cell lines and human head and neck tumors.

K. Ishida, Taka-Aki Sato, H. Osada, 2003, Cancer letters.

Secretion of Heparanase Protein Is Regulated by Glycosylation in Human Tumor Cell Lines*

K. Ishida, H. Osada, S. Simizu, 2004, Journal of Biological Chemistry.

Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.

K. Ishida, H. Osada, S. Simizu, 2004, Bioorganic & medicinal chemistry letters.

Heparanase as a molecular target of cancer chemotherapy

K. Ishida, H. Osada, S. Simizu, 2004, Cancer science.

On‐Chip Fragment‐Based Approach for Discovery of High‐Affinity Bivalent Inhibitors

K. Ishida, H. Osada, S. Simizu, 2009, Chembiochem : a European journal of chemical biology.